Presentations
-
March 17, 2023
The Rare Disease Clinical Outcome Assessment Consortium: Aiming to Fulfill Unmet Drug Development Endpoint Measurement Needs
Appropriate endpoint selection for rare disease trials is challenging. The Rare Disease Clinical Outcome Assessment (COA) Consortium’s aim is the creation of a resource of publicly available COAs deemed fit-for-purpose as trial endpoint measures. You can view the full presentation here. -
February 17, 2023
C-Path Stands with Bruce Willis, Neurodegenerative Disease Community After FTD Diagnosis
C-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal Degeneration (FTD) diagnosis yesterday. Also known as frontotemporal degeneration, the Association for Frontotemporal Degeneration (AFTD) defines FTD as a group of brain disorders caused by degeneration of the frontal and/or temporal lobes of the... - January 5, 2023
- November 30, 2022
- November 9, 2022
